mRNA-1651
Phase 1RNA therapy
ModernamRNA-1651 is one of 55 therapeutic programs targeting Kidney Cancer. It is currently in Phase 1.
1
Indications
0
Total Trials
0
Active Trials
54
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
216 competitors in Kidney Cancer
#DrugCompanyPhaseTrials
1Nexavar
BayerPhase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Avastin
BBio-Thera Solutions
Phase 3
Afinitor
NovartisPhase 3
Thalomid
Bristol-Myers SquibbPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Sutent
PfizerPhase 2
Lenvima
EisaiPhase 3
Prolia
AmgenPhase 3
Depo-Provera
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for mRNA-1651. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Modality
- RNA therapy
- Highest Phase
- Phase 1
- Company